Register for our free email digests:
Zavante Therapeutics Inc.
Division of Nabriva Therapeutics PLC
www.zavante.com
Latest From Zavante Therapeutics Inc.
Keeping Track: US FDA Receives Submissions Galore As Year Ends
A roundup of new applications submitted to FDA’s Center for Drug Evaluation and Research.
Keeping Track: FDA Starts November With A Bang
The latest drug development news and highlights from our FDA Performance Tracker.
Finance Watch: Investment In Novel Antibacterials Gets A New Boost With Qpex Launch
Repeat antibiotic entrepreneurs raised $33m to launch Qpex with assets from The Medicines Co. Also, Taiho increases VC fund to $300m and TP Therapeutics raises $80m.
Finance Watch: Summer Heat Extends To Biopharma IPOs With Nine In July, 45 This Year
Public Company Edition: Nine more biopharma companies launched IPOs in the US in July, bringing the 2018 total to 45 first-time offerings – three more than in all of 2017. Bluebird's $632.5m offering leads recent follow-on public offerings.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Therapeutic Areas
- Gastrointestinal
- Infectious & Viral Diseases
- Respiratory, Pulmonary
- Alias(es)
- Ownership
- Private
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Nabriva Therapeutics PLC
- Senior Management
-
Ted Schroeder, Pres. & CEO
EJ Ellis-Grosse, PhD, CSO
Cam Gallagher, CBO - Contact Info
-
Zavante Therapeutics Inc.
Phone: (610) 816-6640
1000 Continental Dr., Ste. 600
King of Prussia, PA 19406
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice